Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Subcutaneous Alemtuzumab in B-CLL
NCT00162851Phase 2Completed
- Sponsor
- Karolinska University Hospital
- Start
- Apr 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Karolinska University Hospital. Primary endpoint: Safety and Tolerability. Started Apr 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00162851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162851.